Although it isn't particularly famed as a dividend stock, Gilead Sciences (NASDAQ: GILD) is nevertheless a consistent payer of such distributions. Reinforcing this, the company -- these days considered a coronavirus stock due to its COVID-19 drug remdesivir -- has declared its latest quarterly dividend.
A dividend of $0.68 per share will be handed out on Sept. 29 to investors of record as of Sept. 15. On Friday's closing stock price, this would yield 3.9%.
Since initiating its payout in February of 2015, the pharmaceutical company has dispensed it in every quarter. Over that stretch of time, it has increased gradually, from an initial $0.43 per share to the present level.
Although Gilead has been a coronavirus stock star due to recent encouraging news about remdesivir's repurposing, its most recently reported quarter wasn't exactly a standout.
As reported on Thursday, the company posted notable declines in headline financials for its second quarter of fiscal 2020. Sales fell by 10% on a year-over-year basis, while it flipped to a bottom-line loss for the period. Stripping out the pricey ($4.9 billion) acquisition of biotech Forty Seven, the company still would have seen an erosion in profit -- earnings per share in that case were $1.11, well down from the $1.72 per share of Q2 2019.
Gilead shares fell by 3.9% on Friday, despite the happy news about the new dividend. The shares declined at a rate considerably deeper than that recorded by the top equity indexes on the day.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 2, 2020
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.